Profile: Calypte Biomedical Corp. offers in vitro testing products to improve the diagnosis of human immunodeficiency virus (HIV) infection, sexually transmitted and other chronic diseases. Our Aware™ BED™ EIA HIV-1 incidence EIA test is used to estimate the rate of new HIV infections in populations, by determining what proportion of a population of HIV-infected individuals were infected within six months of sample collection. Our Aware™ HIV-1/2 BSP test is a single-use, visually read, in vitro immunoassay for the detection of antibodies to human immunodeficiency virus (HIV) Type 1 (HIV-1) and Type 2 (HIV-2) in human whole blood, serum or plasma specimens.
The company was founded in 1988, has revenues of USD 1-5 Million, has ~60 employees and is ISO 9001 certified.
44 Products/Services (Click for related suppliers)
|
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• (FDA Code: MZF) |
• |
• |
• |
• |
• |
• (FDA Code: NNI / 864.3250) A specimen transport and storage container, which may be empty or prefilled, is a device intended to contain biological specimens, body waste, or body exudate during storage and transport in order that the matter contained therein can be destroyed or used effectively for diagnostic examination. If prefilled, the device contains a fixative solution or other general purpose reagent to preserve the condition of a biological specimen added to the container. This section does not apply to specimen transport and storage containers that are intended for use as part of an over-the-counter test sample collection system for drugs of abuse testing. |
• (FDA Code: NNK / 864.3250) |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |
• |